Central Nervous System Neoplasms Clinical Trial
Official title:
The Safety and Efficacy of MULTIHANCE at the Dose of 0.10 mmol/kg in Magnetic Resonance Imaging of the Central Nervous System in Pediatric Patients Who Are Less Than 2 Years of Age
Collection of already existing data and images for patients < 2 years of age having MultiHance administration for a MRI of the brain or spine. MR Images will be reviewed during a prospectively designed blinded reading of the images.
n/a
Observational Model: Case-Only, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00329589 -
A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients
|
Phase 1 | |
| Completed |
NCT03257631 -
A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
|
Phase 2 | |
| Terminated |
NCT02095353 -
Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients
|
||
| Recruiting |
NCT04541082 -
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
|
Phase 1 | |
| Active, not recruiting |
NCT01180881 -
Neurobehavioral Functioning in Pediatric Brain Tumor Patients After Proton Beam Radiation Treatment
|
||
| Completed |
NCT00822432 -
Coproporphyrine Isomers and Methotrexate Elimination
|
N/A | |
| Completed |
NCT03750188 -
Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs
|
||
| Completed |
NCT03188354 -
Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System Lymphoma
|
N/A | |
| Completed |
NCT03147989 -
Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients
|
||
| Active, not recruiting |
NCT03434262 -
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT05850377 -
5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas
|
||
| Terminated |
NCT01582152 -
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04525014 -
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
|
Phase 1 | |
| Terminated |
NCT02692898 -
Biomarker Analysis of Central Nervous System Tumors
|
||
| Not yet recruiting |
NCT04671368 -
Diagnostic Efficiency of Artificial Intelligence for Surgical Neuropathology
|
N/A | |
| Completed |
NCT00328458 -
EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients
|
Phase 1 | |
| Recruiting |
NCT04859543 -
Pediatric Prospective Personalized Immune and Target Identification Trial
|
N/A | |
| Terminated |
NCT04096716 -
Mapping Draining Lymph Nodes in CNS Malignancies
|
Phase 1 | |
| Completed |
NCT01931098 -
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
|
Phase 2 | |
| Recruiting |
NCT05386108 -
Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer
|
Phase 1/Phase 2 |